Clinical trial
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2…
NCT00002945 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00002945 |
|---|---|
| Title | High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia |
| Official title | High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy |
| Enrollment | 61 |
| Start date | Dec 1, 1996 |
| Primary completion | Aug 1, 2001 |
| Completion | Aug 1, 2011 |
| First posted | Apr 16, 2003 |
| Last update posted | Apr 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: